Overview

  • Product nameAnti-Nmnat1 antibody [2642C5a]
    See all Nmnat1 primary antibodies
  • Description
    Mouse monoclonal [2642C5a] to Nmnat1
  • Tested applicationsSuitable for: Dot blot, WBmore details
  • Species reactivity
    Reacts with: Recombinant Fragment
    Predicted to work with: Human
  • Immunogen

    Recombinant fragment: TVVKGIISPV GDAYKKKGLI PAYHRVIMAE LATKNSKWVE VDTWESLQKE WKETLKVLRH HQEKLEASDC DHQQNSPTLE RPGRKRKWTE TQDSSQKKSL EPKTKAVP, corresponding to internal sequence amino acids 42-149 of Human Nmnat1

Properties

Applications

Our Abpromise guarantee covers the use of ab84855 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Dot blot Use at an assay dependent dilution.
WB Use at an assay dependent dilution. Predicted molecular weight: 32 kDa.

Target

  • FunctionCatalyzes the formation of NAD(+) from nicotinamide mononucleotide (NMN) and ATP (PubMed:17402747). Can also use the deamidated form; nicotinic acid mononucleotide (NaMN) as substrate with the same efficiency (PubMed:17402747). Can use triazofurin monophosphate (TrMP) as substrate (PubMed:17402747). Also catalyzes the reverse reaction, i.e. the pyrophosphorolytic cleavage of NAD(+) (PubMed:17402747). For the pyrophosphorolytic activity, prefers NAD(+) and NaAD as substrates and degrades NADH, nicotinic acid adenine dinucleotide phosphate (NHD) and nicotinamide guanine dinucleotide (NGD) less effectively (PubMed:17402747). Involved in the synthesis of ATP in the nucleus, together with PARP1, PARG and NUDT5 (PubMed:27257257). Nuclear ATP generation is required for extensive chromatin remodeling events that are energy-consuming (PubMed:27257257). Fails to cleave phosphorylated dinucleotides NADP(+), NADPH and NaADP(+) (PubMed:17402747). Protects against axonal degeneration following mechanical or toxic insults.
  • Tissue specificityWidely expressed with highest levels in skeletal muscle, heart and kidney. Also expressed in the liver pancreas and placenta. Widely expressed throughout the brain.
  • PathwayCofactor biosynthesis; NAD(+) biosynthesis; NAD(+) from nicotinamide D-ribonucleotide: step 1/1.
    Cofactor biosynthesis; NAD(+) biosynthesis; deamido-NAD(+) from nicotinate D-ribonucleotide: step 1/1.
  • Involvement in diseaseLeber congenital amaurosis 9
  • Sequence similaritiesBelongs to the eukaryotic NMN adenylyltransferase family.
  • Cellular localizationNucleus.
  • Information by UniProt
  • Database links
  • Alternative names
    • EC 2.7.7.1 antibody
    • LCA9 antibody
    • Leber's congenital amaurosis 9 antibody
    • NaMN adenylyltransferase 1 antibody
    • nicotinamide nucleotide adenylyltransferase 1 antibody
    • Nicotinamide-nucleotide adenylyltransferase 1 antibody
    • Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1 antibody
    • nicotinate nucleotide adenylyltransferase 1 antibody
    • Nicotinate-nucleotide adenylyltransferase 1 antibody
    • NMN adenylyltransferase 1 antibody
    • NMN/NaMN adenylyltransferase 1 antibody
    • NMNA1_HUMAN antibody
    • Nmnat 1 antibody
    • Nmnat1 antibody
    • OTTHUMP00000001731 antibody
    • OTTHUMP00000001732 antibody
    • OTTHUMP00000035892 antibody
    • PNAT 1 antibody
    • PNAT1 antibody
    • pyridine nucleotide adenylyltransferase 1 antibody
    see all

Anti-Nmnat1 antibody [2642C5a] images

References for Anti-Nmnat1 antibody [2642C5a] (ab84855)

ab84855 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab84855.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"